Show simple item record

dc.contributor.advisorBates, Robert B.en_US
dc.contributor.authorStessman, Chad Christian, 1972-
dc.creatorStessman, Chad Christian, 1972-en_US
dc.date.accessioned2013-04-18T09:56:55Z
dc.date.available2013-04-18T09:56:55Z
dc.date.issued1998en_US
dc.identifier.urihttp://hdl.handle.net/10150/282652
dc.description.abstractThe synthesis of dolastatin 11 was repeated on a much larger scale. Most of the yields and reaction conditions in the original synthesis were improved upon. Several problems that arose in the scale up were solved. The synthetic dolastatin 11 was obtained for the first time. The synthetic dolastatin 11 had good activity against a variety of cancer cell lines. The structure of the major by-product of the dolastatin 11 synthesis was determined. Several analogs of dolastatin 11 were synthesized. Testing results on the beta-alanine analog of dolastatin 11 showed it to have similar activity to the natural product. Molecular modeling studies on dolastatin 11 in both chloroform and water were pursued. The molecular modeling structure results in chloroform were consistent with NOE and coupling constant evidence. Molecular modeling calculations were also carried out on several dolastatin 11 analogs. These calculations combined with the testing results on dolastatin 11 and its beta-alanine analog indicate that the lowest energy conformation calculated for dolastatin 11 in chloroform may be the most active conformation.
dc.language.isoen_USen_US
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.en_US
dc.subjectHealth Sciences, Pharmacology.en_US
dc.subjectChemistry, Biochemistry.en_US
dc.subjectChemistry, Organic.en_US
dc.subjectHealth Sciences, Oncology.en_US
dc.titleSynthesis of dolastatin 11 and analogs: Molecular modeling studies in this seriesen_US
dc.typetexten_US
dc.typeDissertation-Reproduction (electronic)en_US
thesis.degree.grantorUniversity of Arizonaen_US
thesis.degree.leveldoctoralen_US
dc.identifier.proquest9831817en_US
thesis.degree.disciplineGraduate Collegeen_US
thesis.degree.disciplineChemistryen_US
thesis.degree.namePh.D.en_US
dc.description.noteThis item was digitized from a paper original and/or a microfilm copy. If you need higher-resolution images for any content in this item, please contact us at repository@u.library.arizona.edu.
dc.identifier.bibrecord.b38626007en_US
dc.description.admin-noteOriginal file replaced with corrected file October 2023.
refterms.dateFOA2018-09-05T20:16:00Z
html.description.abstractThe synthesis of dolastatin 11 was repeated on a much larger scale. Most of the yields and reaction conditions in the original synthesis were improved upon. Several problems that arose in the scale up were solved. The synthetic dolastatin 11 was obtained for the first time. The synthetic dolastatin 11 had good activity against a variety of cancer cell lines. The structure of the major by-product of the dolastatin 11 synthesis was determined. Several analogs of dolastatin 11 were synthesized. Testing results on the beta-alanine analog of dolastatin 11 showed it to have similar activity to the natural product. Molecular modeling studies on dolastatin 11 in both chloroform and water were pursued. The molecular modeling structure results in chloroform were consistent with NOE and coupling constant evidence. Molecular modeling calculations were also carried out on several dolastatin 11 analogs. These calculations combined with the testing results on dolastatin 11 and its beta-alanine analog indicate that the lowest energy conformation calculated for dolastatin 11 in chloroform may be the most active conformation.


Files in this item

Thumbnail
Name:
azu_td_9831817_sip1_c.pdf
Size:
5.891Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record